Immutep Limited Faces Class Action Lawsuit Over Securities Law Violations
Immutep Limited Under Legal Scrutiny for Securities Violations
On July 6, 2026, the DJS Law Group announced a class action lawsuit against Immutep Limited, a biopharmaceutical company listed on NASDAQ under the ticker symbol IMMP. The lawsuit focuses on violations of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), as well as Rule 10b-5, which prohibits fraudulent activities in the context of securities transactions.
Background of the Lawsuit
The DJS Law Group is reaching out to investors who purchased shares of Immutep during the class period spanning from March 24, 2025, to March 12, 2026. During this time, it is alleged that the company communicated false and misleading statements regarding its drug trials. The pivotal point of contention involves the TACTI-004 trial concerning eftilagimod alfa (efti). On January 30, 2026, Immutep purportedly stated that the trial was showing **
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.